Clinical Trials Logo

Filter by:
NCT ID: NCT06409390 Recruiting - Clinical trials for Metastatic Breast Cancer

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Start date: April 26, 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.

NCT ID: NCT06409195 Recruiting - Clinical trials for Non-Melanoma Skin Cancers

A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers

Start date: March 25, 2024
Phase: Phase 2
Study type: Interventional

Open-Label study evaluating safety and efficacy of SM-020 Gel 1.0% in subjects with Seborrheic Keratoses and Non-Melanoma Skin Cancers (i.e. Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ). Subjects will be enrolled into 1 of 5 cohorts. Each cohort will enroll approximately 5-10 subjects with at least 1 eligible lesion to be treated. A maximum of 5 lesions may be enrolled per subject. Treatment for all subjects and all lesions will be twice daily for approximately 28 days. Post treatment, residual lesions may be excised per standard of care for histological evaluation. The duration of the study is estimated to be approximately up to 12 weeks from the beginning of the Screening period until the last subject's last visit.

NCT ID: NCT06409130 Recruiting - Clinical trials for Alcohol-related Liver Disease

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Start date: May 20, 2024
Phase: Phase 2
Study type: Interventional

The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or "dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.

NCT ID: NCT06409065 Recruiting - Cancer Clinical Trials

Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers

Start date: January 9, 2024
Phase: N/A
Study type: Interventional

The goal of this behavioral research study is to learn about the effects of two different supportive care programs on patients' and their family caregivers' psychological wellbeing and overall quality of life.

NCT ID: NCT06409013 Recruiting - Soft Tissue Sarcoma Clinical Trials

Evaluation of Tumor Resection Guided by Intraoperative Indocyanine Green Dye Fluorescence Angiography in Patients With Sarcoma

Start date: March 14, 2024
Phase:
Study type: Observational

This study evaluates the effectiveness of intraoperative indocyanine green dye and fluoroscopic technology in confirming negative margins after tumor removal.

NCT ID: NCT06409000 Recruiting - Clinical trials for Malignant Solid Neoplasm

Evaluation of 3D Surface Scanning for Virtual-CT Based Radiation Therapy Treatment Planning

Start date: January 19, 2021
Phase:
Study type: Observational

This study evaluates if three dimensional (3D) surface images can be used instead of the standard computed tomography (CT) scans for treatment planning in electron radiation therapy. 3D scanning has previously been used by several groups to design patient-specific devices to be 3D printed, and as has shown excellent agreement with CT obtained surfaces. Using 3D surface imaging instead of x-ray based CT, benefits include: no ionizing radiation used to produce images, shorter time between patient consultation and treatment, and ability to produce and evaluate patient-specific devices for electron therapy earlier in the treatment planning process. This study may help researchers learn how 3D surface scanning may be used to produce a virtual CT image of patient surfaces, and accurately replace traditional planning CT for treatment planning of electron based radiation therapy.

NCT ID: NCT06408818 Recruiting - Parenting Clinical Trials

Study of an Online Program to Help Parents Talk With Their Tween Children About Health, Gender, Body-Image, and Relationships

Start date: May 6, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to learn if Media Aware Parent - Tween, an online program for parents of children ages 9-12, helps parents have effective conversations with their child about health and media.

NCT ID: NCT06408662 Recruiting - Tourette Syndrome Clinical Trials

Remote Delivery of a Mindfulness-based Intervention for Tics

MBIT
Start date: May 23, 2024
Phase: N/A
Study type: Interventional

This research study is being done to compare a mindfulness-based intervention for tics (MBIT) to psychoeducation with relaxation and supportive therapy (PRST) for individuals with Tourette's syndrome or Persistent Tic Disorders (collectively TS). It is the investigator's hope that this information cam be used to improve current treatments for individuals with TS.

NCT ID: NCT06408350 Recruiting - HIV Clinical Trials

Optimal Intervention to Full Viral Suppression: Text Me, Alexis!

Start date: April 11, 2024
Phase: N/A
Study type: Interventional

Text Me, Alexis! is a three-arm randomized controlled trial (RCT) to determine the optimal and most cost-effective intervention for advancing trans women living with HIV to full viral suppression. Participants will be randomized (1:1:1) to Peer Health Navigation (PHN) alone, SMS (text messaging) alone, or PHN+SMS. Participants in the PHN alone and PHN+SMS arms will receive unlimited navigation sessions over 3 months. Participants in the SMS alone and PHN+SMS arms will receive 3 daily theory-based text messages for 90 days for a total of 270 unique scripted messages.

NCT ID: NCT06408220 Recruiting - Gastric Carcinoma Clinical Trials

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

Start date: June 11, 2024
Phase: N/A
Study type: Interventional

This clinical trial evaluates the usefulness of various risk assessment tests, including Helicobacter pylori (H. pylori) breath testing, questionnaires, and endoscopies for identifying participants at high risk for stomach cancer. H. pylori is a bacteria that causes stomach inflammation and ulcers in the stomach. People with H. pylori infections may be more likely to develop cancer in the stomach. H. pylori breath testing can help identify the presence of H. pylori infection in a participant and help identify if the participant may be at a higher risk of developing stomach cancer. An endoscopy uses a thin, flexible lighted tube that is inserted inside the esophagus, stomach, and first part of the small intestine. This allows the doctor to see and look for abnormal areas that may need to be biopsied. Risk assessment including H. pylori evaluation, questionnaires, and endoscopies may help identify participants at high risk for stomach cancer and may be a useful screening tool for earlier stomach cancer diagnosis.